The Morning Cup: The Abortion Pill Is Back — For Now
The Supreme Court just hit pause on the 5th Circuit’s chaos. But the real fight is just beginning.
The Supreme Court stepped in Monday to temporarily restore full access to mifepristone — the medication used in more than 60% of abortions nationwide — after a federal appeals court spent the weekend throwing abortion policy into freefall.
Here’s what happened, and why it’s not over.
Friday Night: The 5th Circuit Drops a Bomb
The U.S. Court of Appeals for the 5th Circuit ruled Friday that mifepristone can no longer be prescribed via telehealth or delivered by mail — anywhere in the United States. Not just in Louisiana. Not just in states with abortion bans. Everywhere.
The ruling came in a lawsuit filed by Louisiana Attorney General Liz Murrill, who argued that the FDA’s rules allowing mail access to mifepristone undermined her state’s near-total abortion ban. A three-judge panel agreed, immediately reinstating an in-person-only dispensing requirement that the FDA had lifted years earlier — first during COVID, then made permanent in 2023.
The ruling took effect instantly. Patients with prescriptions already in hand. Appointments already scheduled. Pharmacies in New York, Washington, Minnesota — states where abortion is fully legal — suddenly operating in legal uncertainty overnight.
The Weekend: Manufacturers Race to SCOTUS
Danco Laboratories and GenBioPro — the two companies that manufacture mifepristone — didn’t wait. Both filed emergency applications with the Supreme Court on Saturday, arguing the 5th Circuit had created immediate, irreparable harm.
Danco called the ruling “unprecedented.” GenBioPro said it had “unleashed regulatory chaos.” Both asked the Court to pause the 5th Circuit’s order while the case works its way through the legal system.
The emergency application landed first with Justice Samuel Alito — because cases from the 5th Circuit go to him — but was expected to be referred to the full Court.
Monday: SCOTUS Grants the Stay
The Supreme Court granted the emergency stay. Mail access and telehealth prescriptions for mifepristone are temporarily restored while litigation continues.
It’s a win. But it’s a temporary one.
Why This Isn’t Over
The last time this drug was before the Supreme Court — in 2024 — the justices unanimously declined to restrict access. But they didn’t rule on whether the FDA was right to expand access in the first place. They punted, saying the doctors and anti-abortion groups who brought that case didn’t have legal standing to sue.
Louisiana is a different kind of plaintiff. The state argues it has standing because mifepristone is being mailed into Louisiana, directly undermining its abortion ban. That argument carries more legal weight than a group of doctors claiming generalized objections. If the Court agrees Louisiana can sue, they’ll have to actually answer the question they’ve been avoiding: does the FDA have the authority to allow mail access to mifepristone?
With a 6-3 conservative supermajority, that’s not a question abortion rights advocates want answered right now.
There’s also a parallel threat quietly moving in the background. The Trump administration is conducting its own FDA “safety review” of mifepristone — one the ACLU has described as a thinly veiled attempt to build a case for additional restrictions. That review has a report due in October 2026.
The court battle and the regulatory battle are running simultaneously. Either one could end mail access to the most commonly used abortion medication in the country.
What It Means for Real People
Mifepristone has been FDA-approved since 2000. It has fewer reported side effects than Viagra or penicillin. More than a quarter of all abortions in the United States are now prescribed via telehealth — a number that has grown significantly since Roe was overturned in 2022, precisely because clinic access has been stripped away in state after state.
The 5th Circuit’s ruling, had it stood, would have forced patients in rural areas, low-income patients, survivors of intimate partner violence, and people with disabilities to travel — sometimes hundreds of miles — just to pick up a pill. In states with bans, it would have closed one of the last doors still open.
The stay keeps that door open. For now.
The case is Louisiana v. FDA. Watch for the Supreme Court’s next move — and the FDA’s October review. Both could reshape abortion access in America.
If this was useful, here’s how to stay in the loop.
Follow me on Threads for daily political coverage — no spin, no jargon, just what’s actually happening and why it matters. Subscribe to the newsletter for deeper dives like this one delivered straight to your inbox.
And if you want to support independent political media made by a regular person who just pays attention — you can buy me a coffee. It goes a long way.
Threads: @seanbartleymusic
Newsletter: seanbartleymusic.com
Support: buymeacoffee.com/seanbartley
Sean